(Q40432267)

20 September 2017

1 reference

title

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections (English)

1 reference

20 September 2017

C M Spencer

1

1 reference

20 September 2017

K L Goa

series ordinal

2

1 reference

20 September 2017

publication date

1 July 1995

1 reference

20 September 2017

1 reference

20 September 2017

volume

50

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

176-196

1 reference

Examination of some factors responsible for a food-induced increase in absorption of atovaquone

20 September 2017

cites work

1 reference

12 December 2020

Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Admission of AIDS patients to a medical intensive care unit: causes and outcome

1 reference

12 December 2020

Prevention and treatment of Pneumocystis carinii pneumonia

1 reference

12 December 2020

Treatment of infections in the patient with acquired immunodeficiency syndrome

1 reference

12 December 2020

Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum

1 reference

12 December 2020

Toxoplasmic encephalitis in AIDS.

1 reference

12 December 2020

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

1 reference

12 December 2020

Neurologic manifestations of HIV infection

1 reference

12 December 2020

A radiometric method for objectively screening large numbers of compounds against Pneumocystis carinii in vitro

1 reference

12 December 2020

Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia

1 reference

12 December 2020

Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate

1 reference

12 December 2020

Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

1 reference

12 December 2020

Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.

1 reference

12 December 2020

In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii

1 reference

12 December 2020

An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii

1 reference

12 December 2020

The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine

1 reference

12 December 2020

Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group

1 reference

12 December 2020

Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program

1 reference

12 December 2020

A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Evaluation of the Effect of Drugs on the Cyst Form of Toxoplasma gondii

1 reference

12 December 2020

Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis

1 reference

12 December 2020

Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase

1 reference

12 December 2020

Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii

1 reference

12 December 2020

In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii

1 reference

12 December 2020

566C80, an antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients

1 reference

12 December 2020

Pneumocystis carinii: a deadly opportunist

1 reference

12 December 2020

566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients

1 reference

12 December 2020

Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)

1 reference

12 December 2020

Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Toxoplasma gondii infection in advanced HIV infection

1 reference

12 December 2020

Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization

1 reference

12 December 2020

Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia

1 reference

12 December 2020

Pulmonary infectious complications of human immunodeficiency virus infection. Part II.

1 reference

12 December 2020

The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase

1 reference

12 December 2020

Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model

1 reference

12 December 2020

Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice

1 reference

12 December 2020

Follow-up Bronchoalveolar Lavage in AIDS Patients withPneumocystis cariniiPneumonia:Pneumocystis cariniiBurden Predicts Early Relapse

1 reference

12 December 2020

Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia

1 reference

12 December 2020

Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis

1 reference

12 December 2020

Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study

1 reference

12 December 2020

[Efficacy of atovaquone in resistant toxoplasmosis in AIDS]

1 reference

12 December 2020

Open-label efficacy and safety trial of 42 days of 566C80 for Pneumocystis carinii pneumonia in AIDS patients

1 reference

12 December 2020

Adverse Reactions to Trimethoprim-Sulfamethoxazole in Patients with the Acquired Immunodeficiency Syndrome

1 reference

12 December 2020

10.2165/00003495-199550010-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1030971911

0 references

1 reference